Frank Behrens discusses the findings from a phase 3 trial comparing upadacitinib with placebo and adalimumab in patients with psoriatic arthritis and an inadequate response to non-biologic DMARDs (7:48).
05-06-2020 | EULAR 2020 | Conference coverage | Video